Indeed, while several studies failed to detect GLP1R mRNA in the human or rodent liver [13, 14], it is conceivable that GLP1R might be expressed in nonhepatic cells, such as immune cells or intrahepatic blood vessels [12]
At e-Surgery, we understand how important it is to have affordable, effective options
Patient Prefer
With hands-on involvement from Rafael Olartecoechea and the dedicated Vive Ageless team, you receive a level of personalized care that keeps you motivated, supported, and on track at every stage of your journey
This includes individuals with: Diagnosed MASLD or MASH, where GLP-1 therapy may offer therapeutic benefits but requires monitoring Chronic viral hepatitis (hepatitis B or C), particularly if transaminases are elevated Autoimmune hepatitis or other inflammatory liver conditions Cirrhosis or advanced fibrosis, where specialist consultation may be appropriate despite generally not requiring dose adjustment History of drug-induced liver injury from other agents For these patients, baseline comprehensive liver assessmentincluding liver enzymes, synthetic function tests (albumin, INR), and potentially imaging or non-invasive fibrosis markers (such as FIB-4 or ELF)helps establish a reference point for monitoring treatment effects